Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study.

Flandre, Thierry D; Mansfield, Keith G; Espié, Pascal J; Rubic-Schneider, Tina; Ulrich, Peter

Flandre, Thierry D; Mansfield, Keith G; Espié, Pascal J; Rubic-Schneider, Tina; Ulrich, Peter.

Affiliation

Flandre TD; Novartis Institutes for Biomedical Research, Basel, Switzerland.
Mansfield KG; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
Espié PJ; Novartis Institutes for Biomedical Research, Basel, Switzerland.
Rubic-Schneider T; Roche, Basel, Switzerland.
Ulrich P; Novartis Institutes for Biomedical Research, Basel, Switzerland.

Toxicol Pathol ; 50(5): 712-724, 2022 07.

Article in En | MEDLINE | ID: mdl-35730205

Subject(s)

Cryptosporidiosis; Cryptosporidium; Opportunistic Infections; Animals; Antibodies, Monoclonal; CD40 Antigens; CD8-Positive T-Lymphocytes; Immunosuppression Therapy; Macaca mulatta

Key words

CD154; CD40; Macaca mulatta; biotherapeutics; immunomodulator; infection; lymphoid system

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Opportunistic Infections / Cryptosporidiosis / Cryptosporidium Limits: Animals Language: En Journal: Toxicol Pathol Year: 2022 Document type: Article

Fulltext

XML

PubMed Links

Search on Google